AU Patent

AU2014202367C1 — Novel pharmaceutical composition

Assigned to Novartis AG · Expires 2024-11-21 · 1y expired

What this patent protects

H:\re\tevven\RPo,1l\DCCREC\658927_LDOiC-29/0420>4 ABSTRACT Disclosed are novel pharmaceutical compositions containing 3'-[(2Z)-[1-(3,4 dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazine]-2' hvdroxy-[1,1'-biphenyl]-3-carboxvlic acid bis-(monoethanolamin…

USPTO Abstract

H:\re\tevven\RPo,1l\DCCREC\658927_LDOiC-29/0420>4 ABSTRACT Disclosed are novel pharmaceutical compositions containing 3'-[(2Z)-[1-(3,4 dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazine]-2' hvdroxy-[1,1'-biphenyl]-3-carboxvlic acid bis-(monoethanolamine)(eltrombopag olamine) and processes for preparing the same.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014202367C1
Jurisdiction
AU
Classification
—
Expires
2024-11-21
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.